Quarterly report · Q3
4544.TEDINET S100SUU5
Period2023-04-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥177.5bn | 2023-04-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥260.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥201.0bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | −¥1.1bn | 2023-04-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | ¥23.7bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | −¥2.9bn | 2023-04-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥22.0bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥23.2bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | −¥3.2bn | 2023-04-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥25.8bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥3.3bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥15.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥18.8bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥3.3bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | ¥18.8bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥284.1bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥297.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥281.9bn | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥140.9bn | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥147.9bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥143.2bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥150.0bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥153.3bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥40.4bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥44.2bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥40.4bn | at 2023-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥44.2bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥30.5bn | at 2022-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥46.5bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥9.4bn | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥32.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥19.2bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥9.2bn | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥29.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥24.9bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥4.6bn | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥10.9bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-58.78 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-26.78 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥275.52 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥331.22 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥57.35 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥275.5 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥331.19 | 2022-04-01 → 2022-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 50.4% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.3% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.4% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-12-31 | −¥4.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-12-31 | −¥4.5bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-12-31 | −¥4.6bn |
| jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥110.2bn |
| jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥110.0bn |
| jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥214m |
| jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | −¥8.6bn |
| jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥50.7bn |
| jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥46.4bn |
| jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥4.3bn |
| jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥11.0bn |
| jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥21.1bn |
| jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥21.1bn |
| jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥4m |
| jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥938m |
| —segment total | revenue | 2023-04-01 → 2023-12-31 | ¥182.0bn |
| —segment total | revenue external | 2023-04-01 → 2023-12-31 | ¥177.5bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥4.5bn |
| —segment total | segment profit | 2023-04-01 → 2023-12-31 | ¥3.4bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥6.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥6.2bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥3.3bn |
| jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥124.9bn |
| jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥124.7bn |
| jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥212m |
| jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥2.7bn |
| jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥61.6bn |
| jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥55.6bn |
| jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥5.9bn |
| jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥23.5bn |
| jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥20.7bn |
| jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥20.6bn |
| jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥15m |
| jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥825m |
| —segment total | revenue | 2022-04-01 → 2022-12-31 | ¥207.1bn |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥201.0bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥6.2bn |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | ¥26.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 485
| Item | Context | Value | Unit |
|---|---|---|---|
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -6167000000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember | 124918000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember | 61555000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember | 20657000000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 207131000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -6167000000 | JPY |
| Net sales | Prior1YTDDuration | 200963000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember | 2654000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember | 23459000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember | 825000000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | 26939000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -3256000000 | JPY |
| Operating income | Prior1YTDDuration | 23683000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember | 109959000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember | 46427000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember | 21125000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 177511000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 177511000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember | 214000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember | 4279000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember | 4000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 4497000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -4497000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember | 110173000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember | 50706000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember | 21129000000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 182009000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -4497000000 | JPY |
| Net sales | CurrentYTDDuration | 177511000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember | -8563000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember | 11043000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember | 938000000 | JPY |
| Operating income | CurrentYTDDuration_ReportableSegmentsMember | 3417000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -4564000000 | JPY |
| Operating income | CurrentYTDDuration | -1147000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-02-14 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第74期第３四半期（自 2023年10月１日 至 2023年12月31日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)H.U.グループホールディングス株式会社 | |
| Company name in english cover page | FilingDateInstant | H.U. Group Holdings, Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)取締役 代表執行役会長 兼 社長 兼 グループCEO 竹内 成和 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都港区赤坂一丁目８番１号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)０３（６２７９）０８０１（代表） | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)執行役 兼 CFO 村上 敦子 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都港区赤坂一丁目８番１号 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |